menu
search
date_range
expand_more
1 Year
login
Sign In
home
Home
explore
Dashboard
bookmark_border
Bookmarks
show_chart
Portfolios
search
Explorer
arrow_drop_down
Funds
Equities
library_books
Library
rss_feed
Insights
link
Pinindices
smartphone
Mobile
arrow_drop_down
App Store
Android
Dashboard
chevron_right
Cancer
Next 60 MidCap Biotech Firms
With market capitalizations between $2bn and $10bn, the performance of the midcap biotech selection has gained momentum
trending_up
118.3%
list
61
Biotechnology - Genetic Revolutions
Small- and Mid-Cap biotech firms at the forefront of DNA manipulations and gene therapies
trending_up
64.2%
list
42
Cancer, Rare Diseases & Cell Therapies
Research Breakthrough and Pricing Challenges
trending_up
54.4%
list
26
article
2
Next 60 Small-Cap Biotech
Selection of small market cap biotech firms, below $2 billion
trending_up
83.4%
list
60
Biotech Movers - a January '23 Surprise
Reversal of the negative 2022 trend of biotech firms has been notable - the industry remains volatile but investments could be rewarding
trending_up
37.1%
list
17
Healthcare Innovation ETFs
Deeply transformative healthcare expectations or ever hopeful promises of basic research advance
trending_up
37.2%
list
9
30 Biotech LargeCap Firms
The biotech firms, with market capitalization exceeding $10 billion, are strong contributors to the industry's performance - Momentum is indicative of the sector's resilience
trending_up
62.5%
list
30
